Immunic Inc. (IMUX) Announces Proposed Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Immunic Inc. (IMUX) Prices 2.18M Share Common Stock Offering at $11.40/Each
June 10, 2020 9:18 AM EDTImmunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the pricing of its previously announced public offering for the offering of 2,175,000 shares of common... More
Immunic Inc. (IMUX) Reports FDA Allowance to Begin Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 9, 2020 7:04 AM EDTImmunic, Inc. (NASDAQ: IMUX) today announced receipt of regulatory allowance from the U.S. Food and Drug Administration (FDA) to initiate its phase 2, CALVID-1 clinical trial of IMU-838, the company's selective oral DHODH inhibitor, in coronavirus disease 2019 (COVID-19) at centers in the United... More
